Traders should monitor resumption of enrollment in MAGNITUDE and MAGNITUDE-2 trials and upcoming interim data readouts, which could serve as next catalysts. The resolution of the FDA hold removes near-term regulatory risk and renews confidence in Intellia’s CRISPR platform’s clinical viability.
Price Chart
Executive Summary
Intellia Therapeutics announced that the FDA has lifted the clinical hold on its Phase 3 MAGNITUDE trial for nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), following implementation of enhanced safety monitoring and patient exclusion criteria. The company is now working to resume enrollment in both MAGNITUDE and MAGNITUDE-2 trials. This clears a key regulatory hurdle for a potential one-time CRISPR-based treatment for ATTR-CM.
Key Facts
- FDA has removed the clinical hold on the MAGNITUDE Phase 3 trial for nex-z in ATTR-CM.
- Clinical hold was initiated in October 2025 due to Grade 4 liver transaminases and elevated bilirubin in one patient.
- Mitigation measures include enhanced liver monitoring, steroid treatment guidance, and new exclusion criteria for liver abnormalities and low ejection fraction (<25%).
- MAGNITUDE trial involves ~1,200 patients; MAGNITUDE-2 (for ATTRv-PN) involves ~60 patients.
- Nex-z is a CRISPR-based therapy designed to inactivate the TTR gene, with potential as a one-time treatment.
- Nex-z has RMAT and Orphan Drug designations from the FDA.
Financial Impact
Removal of clinical hold significantly de-risks the development path for nex-z, a pivotal asset. Successful completion could position nex-z as a first-in-class one-time therapy with multi-billion dollar peak sales potential in ATTR-CM, a life-threatening rare disease with limited treatment options.
Risk Factors
- Potential for additional safety issues to emerge despite new monitoring protocols.
- Enrollment delays due to revised exclusion criteria or international regulatory hurdles.
- Clinical trial results may not meet efficacy endpoints despite safety clearance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247267 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | Press Release | $12.75 $12.58 | ▼ −1.33% | ▼ −1.76% | $11.23 (−11.92%) |
Sep 8, 2026 6w ago | 8-K | $12.21 $11.60 | ▼ −5.00% | ▼ −4.66% | $11.23 (−8.03%) |
Aug 6, 2026 11w ago | 8-K | $11.24 $11.83 | ▲ +5.25% | ▲ +4.04% | $11.23 (−0.09%) |
Jun 15, 2026 19w ago | 8-K | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 13, 2026 19w ago | Press Release | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 1, 2026 21w ago | Press Release | $13.73 $13.54 | ▼ −1.38% | ▲ +1.37% | $11.23 (−18.21%) |
May 11, 2026 24w ago | 8-K | $14.42 $12.69 | ▼ −12.00% | ▼ −11.91% | $11.23 (−22.12%) |
Apr 27, 2026 25w ago | Press Release | $13.20 $13.87 | ▼ −5.08% | ▼ −3.38% | $11.23 (+14.92%) |
Apr 27, 2026 26w ago | 8-K | $13.04 $13.87 | ▲ +6.37% | ▲ +5.96% | $11.23 (−13.88%) |
Apr 3, 2026 29w ago | Press Release | $13.30 $14.26 | ▲ +7.22% | ▲ +3.08% | $11.23 (−15.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers